Search Results

You are looking at 91 - 100 of 1,396 items for :

  • "carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Evaluation and Management of the Unknown Primary Carcinoma of the Head and Neck

Chad E. Galer and Merrill S. Kies

in the management of unknown primary head and neck carcinoma . Arch Otolaryngol Head Neck Surg 2005 ; 131 : 626 – 629 . 2. Califano J Leong PL Koch WM . Second esophageal tumors in patients with head and neck squamous cell carcinoma: an

Full access

Integrating Immunotherapy Into the Management of Renal Cell Carcinoma

Matthew Zibelman and Elizabeth R. Plimack

carcinoma (RCC), a cancer long considered “immunogenic,” is a prominent example. In the 1960s, cases of spontaneous remissions in patients with metastatic RCC (mRCC) were reported, documenting a curious phenomenon unique to few metastatic tumors and

Full access

BRAF Inhibition in BRAF V600E-Positive Anaplastic Thyroid Carcinoma

Annette M. Lim, Graham R. Taylor, Andrew Fellowes, Laird Cameron, Belinda Lee, Rodney J. Hicks, Grant A. McArthur, Christopher Angel, Benjamin Solomon, and Danny Rischin

effective treatments available. For tumors that harbor known targetable mutations, treatments directed at those mutations can be highly effective and well tolerated. 1 , 2 Anaplastic thyroid carcinoma (ATC) is an uncommon, highly aggressive tumor with a

Full access

Diagnostic Delays Are Common Among Patients With Hepatocellular Carcinoma

Nishant Patel, Adam C. Yopp, and Amit G. Singal

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Although its incidence is lower in the United States and Europe, its incidence is rapidly increasing because of a growing number of cases of nonalcoholic

Full access

Merkel Cell Carcinoma Guidelines

Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous tumor that combines the local recurrence rates of infiltrative non-melanoma skin cancer with the regional and distant metastatic rates of thick melanoma. The mortality rate of MCC exceeds that of melanoma, and the 5-year disease-specific survival rate is 64%. These guidelines and most biomedical literature suggest that the workup of a patient with MCC should include chest radiograph and additional studies as clinically indicated. These guidelines, which the NCCN Non-Melanoma Skin Cancer Panel developed as a supplement to those for squamous cell and basal cell skin cancer, also outline treatment strategies.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Prostate Cancer Early Detection, Version 2.2015

Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Robert R. Bahnson, Daniel A. Barocas, Erik P. Castle, William J. Catalona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth B. Etzioni, Thomas Farrington, George P. Hemstreet III, Mark H. Kawachi, Paul H. Lange, Kevin R. Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M. Morgan, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence M. Shaneyfelt, Marc C. Smaldone, Geoffrey Sonn, Preston Sprenke, Andrew J. Vickers, Robert Wake, Dorothy A. Shead, and Deborah Freedman-Cass

. Individual Disclosures of the NCCN Merkel Cell Carcinoma Panel References 1. Siegel RL Miller KD Jemal A . Cancer statistics, 2015 . CA Cancer J Clin 2015 ; 65 : 5 – 29 . 2. National Cancer Institute . Surveillance

Full access

Can Therapy of Hepatitis C Affect the Development of Hepatocellular Carcinoma?

Laura M. Kulik

. Coussens LM Werb Z . Inflammation and cancer . Nature 2002 ; 420 : 860 – 867 . 2. Llovet JM Burroughs A Bruix J . Hepatocellular carcinoma . Lancet 2003 ; 362 : 1907 – 1917 . 3. Bosch FX Ribes J Diaz M . Primary liver cancer

Full access

Impact of the Identification of Nonhuman Genetic Signatures in the Diagnosis and Management of Carcinoma of Unknown Primary

Arantzazu Barquín García, Sara Palacios-Zambrano, Felipe Lozano Alarcón, Beatriz Paumard-Hernández, Miguel Quiralte Pulido, Paloma Navarro, Laura Rodríguez, Isabel Salas Villar, and Jesús García-Donas

megabase in 2008 cost approximately $8,000, but by 2013, it cost $0.10. 2 , 3 Carcinoma of unknown primary (CUP) is one of the greatest challenges for clinicians. 4 Almost all tumors of this type (90%) are initially categorized as adenocarcinomas based

Full access

Optimal Treatment of Unresectable Nonmelanoma Skin Cancers

Thomas Olencki

with cutaneous squamous cell carcinoma (SCC), metastatic basal cell carcinoma (BCC), and metastatic Merkel cell carcinoma (MCC). Dr. Olencki noted the few options available for these rare cancers and a lack of clinical trials for guidance, and shared

Full access

Comparison of Pathologic Stage in Patients Receiving Esophagectomy With and Without Preoperative Chemoradiation Therapy for Esophageal SCC

Bing-Yen Wang, Ping-Yi Lin, Shiao-Chi Wu, Hui-Shan Chen, Po-Kuei Hsu, Chih-Shiun Shih, Chao-Yu Liu, Chia-Chuan Liu, and Yao-Li Chen

Background Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignancies worldwide. Most patients die within 1 year of diagnosis, and the 5-year overall survival (OS) rate is less than 20%. 1 , 2 According to the NCCN